<?xml version='1.0' encoding='utf-8'?>
<document id="30339824"><sentence text="Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1)."><entity charOffset="48-59" id="DDI-PubMed.30339824.s1.e0" text="Vincristine" /><entity charOffset="64-76" id="DDI-PubMed.30339824.s1.e1" text="Daunorubicin" /><pair ddi="false" e1="DDI-PubMed.30339824.s1.e0" e2="DDI-PubMed.30339824.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30339824.s1.e0" e2="DDI-PubMed.30339824.s1.e1" /></sentence><sentence text="In the present study, the molecular docking mechanism based on pharmacodynamic interactions between the ligands AZD1208 and recognized chemotherapy agents (Vincristine and Daunorubicin) with human ATP-binding cassette (ABC) transporters (ABCB1) was investigated"><entity charOffset="156-167" id="DDI-PubMed.30339824.s2.e0" text="Vincristine" /><entity charOffset="172-184" id="DDI-PubMed.30339824.s2.e1" text="Daunorubicin" /><pair ddi="false" e1="DDI-PubMed.30339824.s2.e0" e2="DDI-PubMed.30339824.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30339824.s2.e0" e2="DDI-PubMed.30339824.s2.e1" /></sentence><sentence text=" For the first time, were combined an in silico approaches like molecular docking and ab initio computational simulation based on Density Functional Theory (DFT) to explain the drug-drug interaction mechanism of aforementioned chemotherapy ligands with the transmembrane ligand extrusion binding domains (TMDs) of ABCB1" /><sentence text=" In this regard, the theoretical pharmacodynamic interactions were characterized by using the Gibbs free energy (FEB, kcal/mol) from the best ABCB1-ligand docking complexes" /><sentence text=" The molecular docking results pointing that for the three chemotherapy ABCB1-ligand complexes are mainly based in non-covalent hydrophobic and hydrogen-bond interactions showing a similar toxicodynamic behavior in terms of strength of interaction (FEB, kcal/mol) and very close free binding energies when compared with the FEB-values of the ABCB1 specific-inhibitor (Rhodamine B) = -6"><entity charOffset="144-152" id="DDI-PubMed.30339824.s5.e0" text="hydrogen" /><entity charOffset="368-379" id="DDI-PubMed.30339824.s5.e1" text="Rhodamine B" /><pair ddi="false" e1="DDI-PubMed.30339824.s5.e0" e2="DDI-PubMed.30339824.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30339824.s5.e0" e2="DDI-PubMed.30339824.s5.e1" /></sentence><sentence text="0 kcal/mol used as theoretical docking control to compare with FEB (AZD1208-ABCB1) ∼ FEB (Vincristine-ABCB1) ∼ FEB (Daunorubicin-ABCB1) -6" /><sentence text="2 kcal/mol as average" /><sentence text=" Ramachandran plot suggests that the 3D-crystallographic structure from ABCB1 transporter can be efficiently-modeled with conformationally-favored Psi versus Phi dihedral angles for all key TMDs-residues" /><sentence text=" Though, the results of DFT-simulation corroborate the existence of drug-drug interaction between (AZD1208/Vincristine) &gt; (AZD1208/Daunorubicin)"><entity charOffset="107-118" id="DDI-PubMed.30339824.s9.e0" text="Vincristine" /><entity charOffset="131-143" id="DDI-PubMed.30339824.s9.e1" text="Daunorubicin" /><pair ddi="false" e1="DDI-PubMed.30339824.s9.e0" e2="DDI-PubMed.30339824.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30339824.s9.e0" e2="DDI-PubMed.30339824.s9.e1" /></sentence><sentence text=" These theoretical pieces of evidence have preclinical relevance potential in the design of the new drugs to understand the polypharmacology influence in the molecular mechanism of multiple-drugs resistance, contributing with a higher success in chemotherapy and prognosis of cancer patients" /><sentence text="" /></document>